Overview

Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen

Status:
Completed

Trial end date:
2003-05-01

Target enrollment:

Participant gender:

Summary

Examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (Allegra) and montelukast sodium 10 mg (Singulair) as compared to placebo on skin wheals and flares induced by seasonal allergen.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Fexofenadine
Montelukast
Terfenadine